What we did
Based on the scope, our expert provided a detailed report on the following questions:
- How the anti-cancer molecules are attached to Nanodiamonds for drug delivery?
- How the anti-cancer molecules are attached to Nanodiamonds derivatives for drug delivery?
- What is the advancement in drug delivery after the conjugation of anti-cancer molecules and Nanodiamonds?
- Who are the most active players/companies involved in this field?
- What is the activity of filing of the top players/companies? Is there any licensing opportunity?
- What are the different types of cancer treatment focused on by top players/companies?
The study also aimed at solving some of the major challenges with Nanodiamods such as:
- The potential toxicity of nanoparticles remains one of the major concerns the field of nanoparticle-based drug delivery. NDs cytotoxicity for urothelial cells and the routes of their internalization remains an open question in the aspect of nanodiamond surface.
- In the case of nanoparticles for drug delivery applications, some immediate challenges include the incompatibility of length scales, the complexity of the thermochemical environment surrounding the nanoparticles, and the role of polydispersity in determining properties and performance.
- Synthesizing drug-loaded ND conjugates with uniform and tunable sizes, high loading capacity, efficacy in drug delivery, and versatility in terms of surface functionalization is still a challenge.
- Considerable effort is directed toward eliminating the aromatic shell, but persistent graphitization of subsequent subsurface layers makes perdurable purification a challenge.